T2D: Don’t Sugar Coat It

Should we be thinking differently about type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson (primary care provider), Ms Lucia Novak (Nurse Practitioner), and Dr Joshua Stolker (cardiologist) as they talk about ways to think differently about type 2 diabetes and consider factors in addition to A1C such as comorbidities, recommendations on managing patients with T2D from national endocrinology and cardiology societies, and how the cardiology community can work with the diabetology community to provide the best care for patients with T2D. This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeLucia M. Novak, MSN, ANP-BC, BC-ADMPresident and OwnerDiabetes Consulting ServicesNorth Bethesda, MarylandCo-Executive DirectorCapital Health & Metabolic Center of Capital Diabetes & Endocrine AssociatesCamp Springs and Silver Spring, MarylandJoshua M. Stolker, MDSTEMI DirectorMercy Heart and VascularWashington, MissouriAdjunct Associate ProfessorSaint Louis UniversitySt. Louis, Missouri

What are the prevalence, increased risk, and impact of cardiovascular disease (CVD) among patients with type 2 diabetes (T2D)? Join experts: Dr John Anderson (primary care physician), Dr Pam Taub (cardiologist), and Dr Mark Greathouse (cardiologist) as they review the relationship between T2D and CVD, including how T2D exacerbates CVD and the risk from CVD, and what the national medical associations recommend for patients with T2D and CVD.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseePam Taub, MD, FACCCardiologist and Professor of MedicineDirector, Cardiac Rehabilitation and Wellness CenterUC San Diego HealthSan Diego, CaliforniaMark Greathouse, MDSenior Clinical CardiologistSt. Clair HealthPittsburg, Pennsylvania

What is the impact of insufficient GLP-1 activity in type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson, Dr Javier Morales, and Dr Richard Pratley as they review the role of GLP-1 in glucose regulation, consider the impact of insufficient GLP-1 activity on pancreatic beta cells in patients with T2D, and discuss possibilities to overcome insufficient GLP-1 activity in patients with T2D.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeJavier Morales, MD, FACP, FACEInternal Medicine, Diabetes, and Primary CareAssociate Clinical ProfessorHofstra/Northwell School of Medicine at the Donald and Barbara Zucker School of MedicineLong Island, New YorkRichard E. Pratley, MDInternal Medicine and DiabetesAdventHealth Diabetes InstituteOrlando, Florida

What is the role of endogenous GLP-1 in the pathophysiology of T2D? Join multidisciplinary experts in T2D: Dr John Anderson, Dr Vivian Fonseca, and Dr Jim Gavin as they discuss the fascinating history of GLP-1 discovery and the role of endogenous GLP-1 in the pathophysiology of T2D.This podcast is sponsored by Novo Nordisk and is intended for Healthcare Practitioners.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeJames R. Gavin III, MD, PhDClinical Professor of Medicine, Emory UniversityChief Medical Officer, Healing Our Village, Inc.Atlanta, GeorgiaVivian A. Fonseca, MD, FRCPProfessor of Medicine, Assistant Dean for ResearchTulane UniversityNew Orleans, Louisiana

What do you know about the role of beta-cell dysfunction in the pathophysiology of type 2 diabetes (T2D)? Join primary care experts in T2D: Dr. John Anderson, Dr. Stephen Brunton and Dr. James LaSalle as we discuss the beta-cell function and its critical role in T2D pathogenesis, what clinicians know or should know about it and how it is measured in the clinic, and how our current knowledge of beta-cell function in T2D may affect future research on T2D treatment.This podcast is sponsored by Novo Nordisk and is intended for clinicians. The opinions expressed are those of the speakers and not Novo Nordisk.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeStephen Brunton, MD, FAAFPExecutive DirectorPrimary Care Metabolic GroupWinnsboro, South CarolinaJames LaSalle, DO, FAAFPMedical Arts of Excelsior Springs, Inc.Excelsior Springs, Missouri

What is the burden of the type 2 diabetes (T2D) epidemic? Join experts in T2D: Dr. John Anderson (primary care provider), Dr. Susan Cornell (clinical pharmacist and certified diabetes care and education specialist) and Dr. Doron Schneider (primary care provider) as they discuss the enormous physical, emotional, psychological and economic burden of T2D and its comorbidities on the US healthcare system and on their patients and what they, as clinicians need to do to ease this burden.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeSusan Cornell, BS, PharmD, CDCES, FAPhA, FADCESAssociate Director of Experiential EducationProfessor of Pharmacy PracticeMidwestern University Chicago College of PharmacyDowners Grove, IllinoisDoron Schneider, MD, MBA, FACPVice President, Population Health ServicesTandigm HealthWest Conshohocken, Pennsylvania

What is the impact of COVID-19 on adult patients with type 2 diabetes (T2D) and how do we navigate healthcare when an epidemic and pandemic seemingly join forces to further exacerbate patient outcomes? Join experts in T2D: Dr. John Anderson (primary care provider), Dr. Eden Miller (primary care provider), and Dr. Serge Jabbour (endocrinologist) for an in-depth discussion on how COVID-19 impacts patients with T2D and what you can do to help your patients as new information is discovered during this evolving landscape.This podcast is sponsored by Novo Nordisk and is intended for clinicians. The opinions expressed are those of the speakers and not Novo Nordisk.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeEden Miller, DO, FOMADiabetes Care, Obesity, Family MedicineFounder, Diabetes and Obesity Care, LLCBend, OregonSerge A. Jabbour, MD, FACP, FACEDiabetes, Clinical Trials of Diabetes Treatments, ObesityProfessor of Medicine, Division of Endocrinology, Diabetes, and Metabolic DiseasesDirector, Jefferson Diabetes Center, Division of Endocrinology, Diabetes and Metabolic DiseasesSidney Kimmel Medical College/ Thomas Jefferson UniversityPhiladelphia, PA